However, the naked mRNA molecule is large, hydrophilic and has a high negative charge density, making it difficult to pass through cell membrane. If injected directly into the body without a delivery mechanism, naked mRNA would be rapidly destroyed by enzymes in the bloodstream and tissues before it could reach your cells. The Lipid Nanoparticle (LNP) have evolved as efficient mRNA delivery vectors.
Lipid Nanoparticles for mRNA Delivery
LNPs are currently the most advanced and clinically validated delivery systems for nucleic acids. They solve several fundamental challenges in nucleic acid drug delivery:
- ● Protective Shielding: The LNP encapsulates the fragile mRNA molecule, preventing nuclease-mediated degradation in the bloodstream.
- ● Cellular Entry and Endosomal Escape: LNPs facilitate cellular uptake via endocytosis. Once inside the cell, the LNP triggers an endosomal escape mechanism, safely releasing the mRNA into the cytoplasm where it can be translated into proteins.
- ● Targeted Distribution: By modifying the ratio and chemical structure of the lipid components, LNPs can be directed to specific tissues and organs.
Four Core Components of LNP
An LNP is a self-assembling structure composed of four distinct lipid molecules. Each component serves a critical structural or biological function.
| Core Component | Biological Function |
| Ionizable Lipids | The core functional component. They carry a positive charge in acidic environments, allowing them to bind tightly with negatively charged mRNA and facilitate endosomal escape. In neutral physiological pH (like the bloodstream), they become uncharged, significantly reducing systemic toxicity and preventing rapid immune clearance. |
| Helper Lipids | Typically phospholipids like DSPC or DOPE. They maintain the structural integrity of the nanoparticle, promote fusion with the cell membrane, and influence the overall biodistribution of the drug. |
| Cholesterol | Regulates the fluidity and permeability of the lipid bilayer, enhancing the LNP's mechanical strength. Cholesterol also promotes the binding of specific blood proteins (like Apolipoprotein E), which naturally directs the LNP toward the liver. |
| PEG-Lipids | Though making up a small fraction of the formulation (usually around 1.5%), PEG-conjugated lipids are essential. They prevent LNPs from aggregating during storage and shield them from immune system clearance in the body, extending the drug's circulation half-life. |
PEG-lipids remain a critical component in modern LNP formulations, influencing particle stability, circulation time, and overall delivery performance. At Biopharma PEG, we provide a broad portfolio of PEG-lipids, PEG derivatives, and custom PEGylation solutions to support the development of mRNA therapeutics, gene editing systems, and next-generation nucleic acid delivery platforms. Contact our team to learn more about our PEG solutions for LNP research and manufacturing.
Related Article: The Role of Four Lipid Components Of LNPs
FDA-Approved LNP Therapeutics
LNP technology is commercially and clinically validated. To date, five genetic medicines utilizing LNP delivery systems have received FDA approval.
| Product Name | Company | RNA Type | Ionizable cationic lipids | PEG lipids | Approval Year | Indication |
| Onpattro (Patisiran) | Alnylam | siRNA | DLin-MC3-DMA | PEG2000-DMG | 2018 | hATTR amyloidosis |
| Comirnaty (BNT162b2) | BioNTech/Pfizer | mRNA | ALC-0315 | ALC-0159 | 2020 | COVID-19 |
| Spikevax (mRNA-1273) |
Moderna | mRNA | SM-102 | PEG2000-DMG | 2020 | COVID-19 |
| mRESVIA (mRNA-1345) |
Moderna | mRNA | SM-102 | PEG2000-DMG | 2024 | RSV |
| mNEXSPIKE (mRNA-1283) |
Moderna | mRNA | SM-102 | PEG2000-DMG | 2025 | COVID-19 |
| mFLUSIVA (mRNA-1010) |
Moderna | mRNA | SM-102 | PEG2000-DMG | 2026 | Influenza |
| Onpattro (Patisiran)
Modality: siRNA therapeutic
Indication: Polyneuropathy caused by hereditary transthyretin-mediated amyloidosis (hATTR).
Approved in 2018, this was the first-ever FDA-approved LNP-formulated RNA drug. While it delivers siRNA rather than mRNA, its success established the clinical viability of the LNP platform and paved the way for future mRNA applications.
| Comirnaty (BNT162b2)
Modality: mRNA vaccine
Indication: COVID-19 prevention.
Its massive global deployment proved the unprecedented speed, safety, and scalability of LNP systems in addressing global public health emergencies.
| Spikevax (mRNA-1273)
Modality: mRNA vaccine
Indication: COVID-19 prevention.
Alongside Comirnaty, its clinical and commercial success cemented the LNP platform as the undisputed gold standard for mRNA delivery.
| mRESVIA (mRNA-1345)
Modality: mRNA vaccine
Indication: Respiratory syncytial virus (RSV) in older adults.
Approved in 2024, mRESVIA demonstrated that the mRNA-LNP chassis can be rapidly adapted and successfully applied to other infectious diseases beyond COVID-19.
|mNEXSPIKE (mRNA-1283)
Modality: Next-generation mRNA vaccine
Indication: COVID-19 prevention.
Driven by formulation innovations, this next-generation LNP drug features improved storage stability (reducing strict cold-chain requirements) and optimized immunogenicity, making nucleic acid therapeutics more practical for global distribution.
| mFLUSIVA (mRNA-1010)
Modality: mRNA vaccine
Indication: Influenza
mFlusiva (mRNA-1010) is an mRNA-based influenza vaccine used to prevent flu illness in adults ages 50 years and older. It is the first mRNA-based influenza vaccine approved.
From Liver Delivery to Precision Targeting
Historically, many LNP systems have demonstrated a natural tendency to accumulate in the liver following systemic administration. This characteristic has contributed to the success of several approved RNA therapeutics targeting hepatic diseases. Today, however, the field is moving beyond liver-focused delivery.
Liver Targeting (Default Pathway): When injected intravenously, standard LNPs naturally adsorb Apolipoprotein E (ApoE) in the bloodstream, leading to rapid uptake by hepatocytes in the liver. This mechanism is ideal for treating hepatic diseases or utilizing the liver as a bioreactor to produce and secrete therapeutic proteins systemically.
Lung Targeting: By adjusting the LNP formulation—such as omitting cholesterol or incorporating specific cationic lipids—scientists can alter the biodistribution profile to bypass the liver and target the lungs. This opens new avenues for treating genetic and acquired respiratory diseases.
Spleen Targeting: The spleen is a primary immune organ. LNPs formulated with specific chemical structures (such as imidazole-based lipids) can specifically deliver mRNA to the spleen to highly activate T-cells. This targeted immune activation is a critical strategy for developing potent cancer vaccines.
Expanding Delivery Frontiers: Advanced LNP engineering now allows these vehicles to overcome complex biological barriers. Current platforms can successfully route therapeutic payloads to highly challenging anatomical targets, including hematopoietic stem cells in the bone marrow, pancreatic islet cells, and even the placenta during pregnancy.
The Pipeline: Emerging Clinical Applications
Building on the success of approved therapies, there are currently over 500 LNP-based clinical trials globally. The technology is rapidly expanding into four advanced therapeutic areas:
Personalized Cancer Vaccines: mRNA sequences are customized based on a patient's unique tumor mutational profile. LNPs deliver these vaccines to immune organs, training the body's immune system to identify and eradicate specific cancer cells. Clinical trials of mRNA vaccines against various types of tumors, including melanoma, lung cancer, pancreatic carcinoma, breast cancer and others, are currently underway.
Protein Replacement Therapy: For genetic diseases caused by missing essential proteins, LNPs can deliver the correct genetic instructions (mRNA), enabling the patient's own cells to synthesize the functional proteins they lack.
In Vivo Gene Editing: Tools like CRISPR-Cas9 are too large to cross cell membranes independently. LNPs can co-encapsulate the Cas9 mRNA and guide RNA, enabling single-dose, permanent correction of specific genetic mutations directly within the patient.
In Vivo CAR-T Therapy: Traditional CAR-T therapy requires extracting, modifying, and expanding patient cells in a specialized laboratory—a costly and complex process. Emerging LNP technologies aim to deliver CAR mRNA directly into T-cells inside the patient's body, drastically reducing manufacturing time and treatment costs.
Summary
Lipid nanoparticles have fundamentally changed the future of nucleic acid medicine. By overcoming the biological barriers that once limited mRNA therapeutics, LNPs have enabled the clinical success of vaccines, accelerated the development of gene therapies, and created new opportunities for treating complex diseases.
As advances in lipid chemistry, targeting technologies, and manufacturing continue to evolve, LNPs will remain at the center of next-generation drug delivery—driving the transition from experimental concepts to real-world therapies that can improve patient outcomes worldwide.
References:
[1] He S, Liu S. [Research progress on lipid nanoparticle messenger RNA delivery system]. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2025 Jun 4;54(4):446-454. Chinese. doi: 10.3724/zdxbyxb-2024-0709. PMID: 40468957; PMCID: PMC12382325.
[2] Ibragimova AA, Fedorov AA, Kirilenko KM, Choynzonov EL, Denisov EV, Patysheva MR. mRNA-Based Personalized Cancer Vaccines: Opportunities, Challenges and Outcomes. Acta Naturae. 2025 Oct-Dec;17(4):17-37. doi: 10.32607/actanaturae.27707. PMID: 41479562; PMCID: PMC12755870.
[3] Schürmann PJL, van Breda Vriesman SPE, Castro-Alpízar JA, Kooijmans SAA, Nieuwenhuis EES, Schiffelers RM, Fuchs SA. Therapeutic Application of mRNA for Genetic Diseases. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2025 May-Jun;17(3):e70019. doi: 10.1002/wnan.70019. PMID: 40415711; PMCID: PMC12104968.
Related Articles:
mRNA Vaccines in 2026: FDA-Approved Vaccines, Applications and Future Prospects
In Vivo CAR-T Delivery: mRNA-LNP System
The Applications and Challenges of Lipid Nanoparticles
The Role of Four Lipid Components Of LNPs
PEG Lipids: Definition, Structure & Key Applications
